title: Autophagy: an 'Achilles' heel of tumorigenesis in TSC and LAM.
abstract: Mammalian target of rapamycin (mTOR) complex 1 (mTORC1), which is activated in tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM), is a master regulator of cell growth, cellular metabolism, and autophagy. Treatment of TSC and LAM patients with mTORC1 inhibitors partially decreases the size of brain and kidney tumors, and stabilizes pulmonary function. However, the tumors regrow and lung function continues to decline when treatment is discontinued. We hypothesized that dysregulation of autophagy plays a critical role in the pathogenesis of tumors with mTORC1 hyperactivation and in their response to mTORC1-targeted therapy. We found that cells lacking TSC2 have low levels of autophagy under basal and cellular stress conditions. Using genetic and pharmacological approaches, we discovered that the survival of Tsc2-deficient tumor cells is dependent on autophagy induction. Thus, autophagy inhibitors may have therapeutic potential in TSC and LAM, either as single agent therapy or in combination with mTORC1 inhibitors.
authors: Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
authors: Jane
authors: J
authors: Yu
authors: Andrey
authors: A
authors: Parkhitko
authors: Elizabeth Petri
authors: EP
authors: Henske
mesh_terms: D000818:Animals; D001343:Autophagy; D002471:Cell Transformation, Neoplastic / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D018192:Lymphangioleiomyomatosis / Q000378:metabolism / Q000473:pathology*; D051379:Mice; D014157:Transcription Factors / Q000378:metabolism; D057170:Translational Research, Biomedical; D014402:Tuberous Sclerosis / Q000378:metabolism / Q000473:pathology*
chemical_list: D014157:Transcription Factors